Cannabis Science Inc (OTCMKTS:CBIS) has successfully negotiated an investment prospect, with Crown Baus Capital Corp (OTCMKTS:CBCA), pertaining to its ongoing development assignments, in California and Nevada. CBCA is headed by the CBIS CEO, Raymond C. Dabney and is committed on drug development, financial services, entertainment, media education and high-tech incubation.
The investment is flowing at a time when Cannabis Science has started to secure property development projects. The contracts call for the advancement of state compliant and completely licensed production facilities for medicinal and industrial cannabis. As per a released statement from company, each of these projects is intended at the cultivation and cannabis based medication advancement programs, for critical diseases. The firm also claimed that these projects would generate numerous jobs, in the construction, education, retail, medical and farming industries, in the adjacent areas.
Cannabis Science has reported that it plans to split the investment prospects into one-acre parcels, for its each development task. Moreover, the firm is also looking to advance an investors’ portfolio, supply chain production commerce and partners, throughout the nation. CBCA is most likely to be included a part of the Douglas County advancement task, in Nevada. The phase I of the facility’s advancement is currently underway, with a proposed 33,000 sq-ft of greenhouse area, per acre. Moreover, numerous other contracts for the asset are also in place, which can lead in the development of another 15-acres.
Cannabis Science has also witnessed remarkable success in the marketing of Metered Dose Inhalers (MDI). The firm has confirmed that its distributors have completely sold out the MDI, from the first market-test run carried out in California. As such, with increasing customer demand, the company has ramped up manufacturing of MDIs. California market is one of the most populous cannabis industry in the U.S.
In the last trading session, the stock price of Cannabis Science declined over 5% to close at $0.110.